Topiramate use broadened

The licensed indications for topiramate (Topamax) in the UK have been broadened to ensure consistency with other European countries.

In epilepsy, Topamax monotherapy is now indicated for long-standing (as well as newly diagnosed) epilepsy and adjunctive therapy is no longer restricted to patients who are inadequately controlled on conventional first-line agents.

In migraine, treatment can now be initiated outside specialist care and no longer requires six-monthly review. In addition, prophylactic use of the drug can be considered regardless of the number and severity of migraines.

View Topamax drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

New tablet treatment for eczema

New tablet treatment for eczema

Prescribers have a new oral treatment option for patients...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...